Integrated Diagnostics for Atrial Fibrillation Recurrence: Exploratory Results from the PLACEBO Trial

Area of Science:

• Cardiology
• Biomarkers
• Electrophysiology

Background:

• Atrial fibrillation (AF) is a common arrhythmia with high morbidity and recurrence rates.
• Paroxysmal atrial fibrillation (PAF) requires innovative diagnostic tools for relapse prediction and management.
• Current diagnostic approaches for PAF recurrence are limited.

Purpose of the Study:

• To evaluate the feasibility and prognostic value of integrating cardiopulmonary exercise testing (CPET), echocardiographic indices, and plasma biomarkers for predicting PAF recurrence.
• To identify novel predictors for paroxysmal atrial fibrillation relapses.
• To explore the utility of heart rate variability (HRV) and galectin-3 (GAL3) in forecasting PAF recurrence.

Main Methods:

• A single-center, prospective observational study (PLACEBO trial) of 73 adults with PAF in sinus rhythm.
• Comprehensive assessments included CPET, transthoracic echocardiography, 24-hour Holter monitoring with HRV metrics, and plasma biomarkers (e.g., GAL3).
• Recurrence was defined as any AF episode ≥30 seconds within 12 months.

Main Results:

• Higher standard deviation of RR intervals (SDRR) (OR: 1.061, p=0.021) and GAL3 > 10.95 ng/mL (OR: 5.206, p=0.006) significantly predicted PAF recurrence.
• Lower right ventricular fractional area change (RV FAC) showed a marginally significant association with recurrence (OR: 0.927, p=0.062).
• CPET parameters had limited prognostic value in this cohort.

Conclusions:

• Integrating novel echocardiographic indices, biomarkers (GAL3), and HRV metrics (SDRR) is feasible for predicting PAF recurrence.
• These integrated approaches may offer valuable prognostic insights for personalized risk stratification.
• Larger multicenter studies are necessary to validate these findings and optimize predictive strategies.